Effect of trichosanthin and momorcharins on isolated rat hepatocytes

Ng, T.B.; Liub, W.K.; Tsao, Sai‐Wah; Yeun, H.W.

doi:10.1016/0378-8741(94)90007-8

Cited by 4 publications

(1 citation statement)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Recently, a new study showed that a peptide derived from TCS suppresses the immune response by activating CD8 + CD28 − regulatory T cells and serves as a potential therapeutic agent for immunological diseases ( 19 ). TCS not only has inhibitory activity against various tumor cells but also shows inhibitory activity against several normal somatic cell types, including proximal tubule epithelial cells, hepatocytes and antigen-specific T cells ( 20 – 22 ). Previous studies have reported that TCS can cause neurological reactions in HIV-infected patients and that such toxicity may be due to the effect of TCS on HIV-infected macrophages ( 23 ).…”

Section: Introductionmentioning

confidence: 99%

Trichosanthin suppresses the proliferation of glioma cells by inhibiting LGR5 expression and the Wnt/β-catenin signaling pathway

et al. 2015

View full text Add to dashboard Cite

Studies have indicated that trichosanthin (TCS), a bioactive protein extracted and purified from the tuberous root of Trichosanthes kirilowii (a well-known traditional Chinese medicinal plant), produces antitumor effects on various types of cancer cells. However, the effects of TCS on glioma cells are poorly understood. The objective of this study was to investigate the antitumor effects of TCS on the U87 and U251 cell lines. The in vitro effects of TCS on these two cell lines were determined using a Cell Counting Kit-8 (CCK-8) assay, Annexin V-FITC staining, DAPI staining, Transwell assays, terminal deoxynucleotidyl transferase-mediated dUTP nick end-labeling (TUNEL) assays, 5,5′,6,6′-tetrachloro-1,1′,3,3′-tetraethyl-imidacar-bocyanine iodide (JC-1) staining and western blotting, which was utilized to assess the expression of leucine-rich repeat-containing G protein-coupled receptor 5 (LGR5) and key proteins in the Wnt/β-catenin signaling pathway. Our data indicated that TCS inhibited the proliferation of glioma cells in a dose- and time-dependent manner and played a role in inhibiting glioma cell invasion and migration. Additional investigation revealed that the expression levels of LGR5 and of key proteins in the Wnt/β-catenin signaling pathway were markedly decreased after TCS treatment. The results suggest that TCS may induce apoptosis in glioma cells by targeting LGR5 and repressing the Wnt/β-catenin signaling pathway. In the future, in vivo experiments should be conducted to examine the potential use of this compound as a novel therapeutic agent for gliomas.

show abstract